Linezolid decreases susceptibility to secondary bacterial pneumonia postinfluenza infection in mice through its effects on IFN-γ

Journal of Immunology

Volumn 191, Issue 4, 2013, Pages 1792-1799

  Breslow Deckman, Jessica M ^a   Mattingly, Cynthia M ^a   Birket, Susan E ^a   Hoskins, Samantha N ^a   Ho, Tam N ^a   Garvy, Beth A ^a   Feola, David J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; LINEZOLID; RECOMBINANT GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL PNEUMONIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; FEMALE; IMMUNOMODULATION; IN VIVO STUDY; INFLUENZA; LUNG LAVAGE; MORBIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; WEIGHT REDUCTION;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BRONCHOALVEOLAR LAVAGE FLUID; CD4 LYMPHOCYTE COUNT; COINFECTION; DISEASE SUSCEPTIBILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; INFLUENZA A VIRUS; INTERFERON-GAMMA; LUNG; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; OXAZOLIDINONES; PNEUMONIA, PNEUMOCOCCAL; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD; VIRUS REPLICATION;

EID: 84881392472     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300180     Document Type: Article

References (37)

1. Morens, D. M., J. K. Taubenberger, and A. S. Fauci. 2008. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J. Infect. Dis. 198: 962-970.
2. Sheng, Z. M., D. S. Chertow, X. Ambroggio, S. McCall, R. M. Przygodzki, R. E. Cunningham, O. A. Maximova, J. C. Kash, D. M. Morens, and J. K. Taubenberger. 2011. Autopsy series of 68 cases dying before and during the 1918 influenza pandemic peak. Proc. Natl. Acad. Sci. USA 108: 16416-16421.
3. Schwarzmann, S. W., J. L. Adler, R. J. Sullivan, Jr., and W. M. Marine. 1971. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969. Arch. Intern. Med. 127: 1037-1041.
4. Hageman, J. C., T. M. Uyeki, J. S. Francis, D. B. Jernigan, J. G. Wheeler, C. B. Bridges, S. J. Barenkamp, D. M. Sievert, A. Srinivasan, M. C. Doherty, et al. 2006. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg. Infect. Dis. 12: 894-899.
5. Valiquette, L., B. Cossette, M. P. Garant, H. Diab, and J. Pépin. 2007. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin. Infect. Dis. 45(Suppl. 2): S112-S121.
6. Madhi, S. A., and K. P. Klugman; Vaccine Trialist Group. 2004. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat. Med. 10: 811-813.
7. Klugman, K. P., Y. W. Chien, and S. A. Madhi. 2009. Pneumococcal pneumonia and influenza: a deadly combination. Vaccine 27(Suppl. 3): C9-C14.
8. Kash, J. C., K. A. Walters, A. S. Davis, A. Sandouk, L. M. Schwartzman, B. W. Jagger, D. S. Chertow, Q. Li, R. E. Kuestner, A. Ozinsky, and J. K. Taubenberger. 2011. Lethal synergism of 2009 pandemic H1N1 influenza virus and Streptococcus pneumoniae coinfection is associated with loss of murine lung repair responses. mBio 2: e00172-11.
9. McCullers, J. A., and J. E. Rehg. 2002. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J. Infect. Dis. 186: 341-350.
10. van der Sluijs, K. F., L. J. van Elden, M. Nijhuis, R. Schuurman, S. Florquin, T. Shimizu, S. Ishii, H. M. Jansen, R. Lutter, and T. van der Poll. 2006. Involvement of the platelet-activating factor receptor in host defense against Streptococcus pneumoniae during postinfluenza pneumonia. Am. J. Physiol. Lung Cell. Mol. Physiol. 290: L194-L199.
11. Abramson, J. S., G. S. Giebink, E. L. Mills, and P. G. Quie. 1981. Polymorphonuclear leukocyte dysfunction during influenza virus infection in chinchillas. J. Infect. Dis. 143: 836-845.
12. McNamee, L. A., and A. G. Harmsen. 2006. Both influenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a secondary Streptococcus pneumoniae infection. Infect. Immun. 74: 6707-6721.
13. van der Sluijs, K. F., L. J. van Elden, M. Nijhuis, R. Schuurman, J. M. Pater, S. Florquin, M. Goldman, H. M. Jansen, R. Lutter, and T. van der Poll. 2004. IL- 10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J. Immunol. 172: 7603-7609.
14. van der Sluijs, K. F., M. Nijhuis, J. H. Levels, S. Florquin, A. L. Mellor, H. M. Jansen, T. van der Poll, and R. Lutter. 2006. Influenza-induced expression of indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia. J. Infect. Dis. 193: 214-222.
15. Sun, K., and D. W. Metzger. 2008. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat. Med. 14: 558-564.
16. Shinabarger, D. L., K. R. Marotti, R. W. Murray, A. H. Lin, E. P. Melchior, S. M. Swaney, D. S. Dunyak, W. F. Demyan, and J. M. Buysse. 1997. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob. Agents Chemother. 41: 2132-2136.
17. Takahashi, G., N. Sato, Y. Yaegashi, M. Kojika, N. Matsumoto, T. Kikkawa, T. Shozushima, S. Akitomi, K. Aoki, N. Ito, et al. 2010. Effect of linezolid on cytokine production capacity and plasma endotoxin levels in response to lipopolysaccharide stimulation of whole blood. J. Infect. Chemother. 16: 94-99.
18. Garcia-Roca, P., J. Mancilla-Ramirez, A. Santos-Segura, M. Fernández-Avilés, and E. Calderon-Jaimes. 2006. Linezolid diminishes inflammatory cytokine production from human peripheral blood mononuclear cells. Arch. Med. Res. 37: 31-35.
19. Cottey, R., C. A. Rowe, and B. S. Bender. 2001. Influenza virus. Curr. Protoc. Immunol. Chapter 19: Unit 19.11.
20. Andes, D., M. L. van Ogtrop, J. Peng, and W. A. Craig. 2002. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46: 3484-3489.
21. Keel, R. A., J. L. Crandon, and D. P. Nicolau. 2012. Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions. Antimicrob. Agents Chemother. 56: 3420-3422.
22. Lines, J. L., S. Hoskins, M. Hollifield, L. S. Cauley, and B. A. Garvy. 2010. The migration of T cells in response to influenza virus is altered in neonatal mice. J. Immunol. 185: 2980-2988.
23. Damjanovic, D., M. Divangahi, K. Kugathasan, C. L. Small, A. Zganiacz, E. G. Brown, C. M. Hogaboam, J. Gauldie, and Z. Xing. 2011. Negative regulation of lung inflammation and immunopathology by TNF-α during acute influenza infection. Am. J. Pathol. 179: 2963-2976.
24. Price, G. E., A. Gaszewska-Mastarlarz, and D. Moskophidis. 2000. The role of alpha/beta and gamma interferons in development of immunity to influenza A virus in mice. J. Virol. 74: 3996-4003.
25. Wiley, J. A., A. Cerwenka, J. R. Harkema, R. W. Dutton, and A. G. Harmsen. 2001. Production of interferon-gamma by influenza hemagglutinin- specific CD8 effector T cells influences the development of pulmonary immunopathology. Am. J. Pathol. 158: 119-130.
26. Hayden, F. G., R. Fritz, M. C. Lobo, W. Alvord, W. Strober, and S. E. Straus. 1998. Local and systemic cytokine responses during experimental human influenza A virus infection: relation to symptom formation and host defense. J. Clin. Invest. 101: 643-649.
27. Kaiser, L., R. S. Fritz, S. E. Straus, L. Gubareva, and F. G. Hayden. 2001. Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J. Med. Virol. 64: 262-268.
28. Chen, W. H., F. R. Toapanta, K. A. Shirey, L. Zhang, A. Giannelou, C. Page, M. B. Frieman, S. N. Vogel, and A. S. Cross. 2012. Potential role for alternatively activated macrophages in the secondary bacterial infection during recovery from influenza. Immunol. Lett. 141: 227-234.
29. Denton, A. E., P. C. Doherty, S. J. Turner, and N. L. La Gruta. 2007. IL-18, but not IL-12, is required for optimal cytokine production by influenza virus-specific CD8+ T cells. Eur. J. Immunol. 37: 368-375.
30. Liu, B., I. Mori, M. J. Hossain, L. Dong, K. Takeda, and Y. Kimura. 2004. Interleukin-18 improves the early defence system against influenza virus infection by augmenting natural killer cell-mediated cytotoxicity. J. Gen. Virol. 85: 423-428.
31. Zhang, J. H., H. M. Wei, and Z. G. Tian. 2005. Analysis tissue expression of IFN-gamma in IL-12 and/or IL-18 gene ablated naive mice. Cell. Mol. Immunol. 2: 68-72.
32. Brundage, J. F. 2006. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect. Dis. 6: 303-312.
33. Rothberg, M. B., S. D. Haessler, and R. B. Brown. 2008. Complications of viral influenza. Am. J. Med. 121: 258-264.
34. Hang, T. T., E. J. Choi, J. Y. Song, S. E. Kim, J. Kwak, and Y. K. Shin. 2011. Differential effect of prior influenza infection on alveolar macrophage phagocytosis of Staphylococcus aureus and Escherichia coli: involvement of interferongamma production. Microbiol. Immunol. 55: 751-759.
35. Tarasov, S. A., V. V. Zarubaev, E. A. Gorbunov, S. A. Sergeeva, and O. I. Epstein. 2012. Activity of ultra-low doses of antibodies to gamma-interferon against lethal influenza A(H1N1)2009 virus infection in mice. Antiviral Res. 93: 219-224.
36. Chien, J. W., M. L. Kucia, and R. A. Salata. 2000. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant Gram-positive bacterial infections. Clin. Infect. Dis. 30: 146-151.
37. Ager, S., and K. Gould. 2012. Clinical update on linezolid in the treatment of Gram-positive bacterial infections. Infect Drug Resist 5: 87-102.